Advances in the Use of Positronic Radiomolecular Imaging Agents in the Diagnosis of Parkinson's Disease

The objective of this study was to examine the potential of positron radioactive molecular imaging agents for the diagnosis of Parkinson's disease (PD). With the increasing prevalence of aging and the rising incidence of PD, early diagnosis is of paramount importance to enhance the quality of life of patients. In terms of research methods, this study analyzed the application of positron emission tomography (PET) and computed tomography (CT) technology and its combination with positron radioactive molecular imaging agents in the diagnosis of Parkinson's disease (PD), with particular emphasis on the use of glucose metabolism imaging agents, including 18F-fluoro-2-deoxy-D-glucose (18F-FDG). The findings of the study demonstrate that the integration of PET/CT technology with positron radioactive molecular imaging agents offers a comprehensive approach to the diagnosis of PD. This approach provides valuable functional and metabolic information about the brain of PD patients, and enables the accurate localization of lesions with high specificity and sensitivity, making it a highly effective and well-tolerated diagnostic tool. The utilization of positron radioactive molecular imaging agents in the diagnosis of PD has the potential to significantly enhance the accuracy and efficiency of diagnosis, thereby facilitating early detection and treatment of PD.